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ABSTRACT
Very little is known about how calcium metabolism is regulated in the fetus. and
in particular.lhe role of calcitonin (CT) has not been established. We sludied fetal mice
in which the er gene has been deleted to determine whether er is critically required for
normal fetal-placental calcium homeostasis and skeletal development.
We demonstr.l!ed that homozygous deletion of the er gene eliminated CT but did
not affect maternal or fetal ionized calcium levels. lhe rate of fetal-placental calcium
transfer. serum phosphorus levels. or the amount of mineral present in each fetal skeleton.
It also did not affeclthe gross skeletal morphology. the expression of important bone
markers. fetal serum parathyroid hormone (PTH) levels. or calbindin-D'JI( or Ca- ATPase
expression in placental tissue. However. malernal loss ofer resulted in a reduction in
litter size while both maternal and fetal loss ofCT resulted in a reduction in the
concentration of magnesium in Ihe fetal circulation and possibly in the fetal skeleton.
Our studies also confirm that the genes for CT and the CT-receptor are located in the
murine placenta.
In summary. these results suggesl that CT cannot cross the placenta, that the
maternal absence of CT reduces the tOlal number of fetuses that survive at term. and that
CT may selectively regulate aspects of magnesium metabolism in the fetus. However. it
appears that the complete loss of either maternal or felal er does not perturb the other
measured parameters of fetal-placental calcium homeostasis.
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INTRODUCTION
1.1 Calcium and Bone Homeostasis
Nonnal calcium and bone homeostasis is the process by which humans and other
mammals maintain the calcium concentration in blood at a critical and tightly controlled
level for nonnal cellular functioning as well as maintain a sturdy. fully mineralized
skeleton. Calcium plays a key role in cellular physiology and metabolic regul;llion in all
organisms. In humans specifically. extracellular calcium levels are lightly regulated
within a narrow range so that many tissues can function properly. The intracellular
calcium levels are also tightly controlled. at levels approximately IO,OOO-fold lower than
extracellular calcium. so that calcium can serve as an intracellular second messenger (I).
About 99% percent of the total calcium in the human body is prescnt in bone.
99% percent of this bone calcium is located within the crystalline structure of the mineral
phase. The remaining 1% is rapidly exchangeable with the extracellular calcium pool.
Extracellular calcium acts as the principal substrate for the mineralization of cartilage and
bone (2). In bone, calcium salts provide the structural integrity of the skeleton, while in
the extracellular fluids and cytosol, the ionized calcium concentration [Ca-j is important
in maintaining and controlling biochemical processes (3). Ionized calcium makes up
about 50% of the lotal calcium in serum and extracellular fluids wherea.~ 40% is protein
bound and 10% is complexed with phosphate and citrate (I).
Phosphorus and magnesium are also important components of bone. About 15%
of the phosphorus in the human body is present in the extracellular tluids whereas 85%
plays a structural role in crystalline form in the skeleton (3). About two thirds of the
magnesium present in the adult human body is present in the skeleton while the remaining
one third is present in soft tissues. The magnesium in bone appears to be loc'lIed on the
crystalline structure (3).
In the aduh. calcium and bone homeostasis is maintained by the interactions of
honnones including parathyroid hormone (PTH). calcitriol. and possibly calcitonin (Cf).
PrH is a peptide hormone that controls the level of ionized calcium present in the blood
and extracellular fluids. In response to an increase: in blood calcium. Ihe parathyroid
gland decreases its synthesis and secretion of PTH (2). The main function of PTH is to
increase blood calcium and it achieves this by binding to cell surface receptors
predominantly in bone and kidney. In bone. PTH stimulates the release: of calcium and
phosphate. while in the kidney it stimulates reabsorption of calcium and inhibits the
reabsorption of phosphate (3). Cakitriol also helps keep the level of calcium in serum
within normal range. This steroid hormone acts primarily by increasing intestinal
absorption of calcium from the diet but also has functions in kidney and bone that are
relevant to calcium homeostasis. Calcitriol has functions in other tissues as well.
including the recruitment of stem cells in the bone to become mature osteoclasts. which
release calcium stores from the bone into the circulation. Serum calcium levels tightly
regulate the renal production of calcitriollhrough the actions of PTH and phosphorus (4).
CT is known to regulate blood calcium in lower vertebrates. such as fish. but the role of
Cf and its importance in human calcium homeostasis is less certain (see section 1.3).
1.2 Calcium and Bone Homeostasis in the Fetus
Lillie is known about how fetal calcium and bone homeostasis is regulated. The
fetus must adapt itself in such a way so as to meet its sp«:ial needs during development.
These special needs are that I) the fetus must ensure that it receives enough calcium to
fully mineralize its skeleton by the time ofb;"h and 2) at the same time, the fetus faces
the challenge of maintaining a calcium concentration in the blood that is higher than the
normal adult (and maternal) level (5). In order to achieve these goals. the fetus must
make use of the placenta. kidneys. bone and intestine (reviewed in (6)).
The known calciotropic hormones and other possible (as yet unknown) factors are
responsible for regulating blood calcium and directing calcium into the skeleton as it
develops. Evidence suggests that born PTH and PTH-related protein (PTHrP) are
required for normal regulation of fetal blood calcium through their actions on fetal bone
and kidneys (5). However. PTH has been shown to have a greater impact on blood
calcium regulation than PTHrP (7) (8). That is. loss of PTH causes a greater lowering of
the blood calcium than loss of PTHrP. while loss of both PTH and PTHrP results in the
lowest blood calcium level. It is possible that other factors such as cr. calcitriol. and the
SCIt steroids are involved. but such findings have yet to be reponed.
The fetus must meet the demands of the mineralizing skeleton by actively
transporting calcium across the placenta: the rate of passive or diffusional now across the
placenta is too slow compared to the daily calcium accretion rate by the skeleton Iale in
gestation. The roles ofPTH. PTHrP. calcitriol. and cr in regulation of placental calcium
transfer have been studied to varying degrees. Evidence suggests that PTHrP is an
important regulator of placental calcium transfer while PTH appears to have no effect (9).
The roles of calcitriol. cr, and the sex steroids remain uncertain (reviewed in (6)).
It is known that the fetus mainlains a higher blood calcium (both lotal and ionized)
than the circulating maternal level and the fetus establishes it3 particular blood calcium
level independently of the circulating maternal blood calcium level (10). The
physiological significance of this fetal hypercalcemia has not been delermined (reviewed
in (6)),
The fetal kidneys may playa role in regulating the fetal blood calcium level by
adjusting the relative reabsorption and excretion of calcium and phosphate. However.
there is little data available on fetal kidney function and its relative importance in
regulating the fetal blood calcium. Renal excretion of calcium (and other minerals) does
not necessarily imply that the felus will experience a permanent loss of calcium since the
urine becomes part of the amniotic nuid which can be swallowed and the calcium made
available again to the fetus. Measurements of the volume and composition of amniotic
nuid are often used as indirect measures of fetal renal function (reviewed in (6)) but are
confounded by the fact that other tissues (such as lungs. placenla, and uterine decidua)
may contribute to the composition of the amniotic nuid.
The fetal skeleton also appears to play an important role in fetal calcium
homeostasis. This is expected since as the skeleton grows and mineralizes. most of the
calcium is present in bone. Evidence suggests that the calcium present in the bone can be
mobilized in response to a reduction in the transfer of calcium from the mOlher to the
fetus. For example, when fetuses are hyperparathyroid. with an even higher blood
calcium than nonnal. the skelelon becomes under-mineralized to help ffi:l.lntain thm
incre:l.Sed blood calcium level (10). Thus, an exch:l.nge between bone calcium :l.nd blood
c:l.lcium is most likely occurring in order 10 maintain the ionized c:l.lcium concenlration in
the blood. In addition. it is known that norm:l.l mineralization of the fetal skeleton
requires int:l.Ct para.thyroid glands:!.S well as adequate delivery of calcium to the fetal
circulation (reviewed in (6)). In the presence of a low blood calcium level. such ilS in
fetal mice thai l:l.Ck PTH. the skeleton organifies nonnally but is significantly under-
mineralized (S).
[.3 Calcitonin
cr is a peptide hormone which functions to regulate blood calcium in fish.
However. the physiological role of CT in human c:l.lcium and skeletal metabolism has not
yet been established. A C:l.nadian scientisl. D. Harold Copp. discovered the hormone in
1961 during perfusion studies of the thyroid and p:l.rathyroid glands of dogs. Copp had
discovered a honnone which W:!.S released by hypercalcemia and acled 10 lower the
plasma calcium. He decided to name the hormone "calcitonin" since it appeared to be
involved in regul:l.ling the level or "tone" of calcium in Ihe body fluids (II). Copp h:l.d
Ihought that the honnone originated in the parathyroid glands. however it was 1:l.ler
confirmed that CT originated in the thyroid gland (12). More specifically. cr is
produced in parafollicular cells oflhe thyroid. called C cells. referring to their
responsibility for CT secretion (13). The C cells arise from the neural crest and migrate
forward to become the ultimobranchial body in lower vertebrates or the parafollicular
cells in humans and related species (14 I.
CT is a 32-amino-acid polypeptide that contains a disulfide bridge between the
cysteine residues in positions I and 7, fonning a seven membered ring at the N tenninal
(15). All CT species have the same basic structure but have been classified into three
main groups. These groups are (I) artiodactyl (porcine. ovine. and bovine). (2) human
and rat, and (3) teleost (salmon, eel. and chicken) (16). The human cr gene contains six
exons and is located on the short arm of chromosome II (2). Differenlial splicing of the
exon regions in the initial gene transcript produces two distinct mature messenger RNAs.
One translates as a 141-residue cr precursor while the other translates as a 128-residue
precursor for calcitonin gene-related peptide (CGRP). cr is the major posttranslational
product ofC cells, whereas CORP (a 37·amino-acid peptide) is the major
posllranslational product in neurons (17).
cr carries out its biologic effects through the CT-receptor which is a a protein-
coupled cell surface receptor that is closely related to the receptor for PTH. The CT-
receptor is robustly expressed in osteoclasts as well as in the kidney and certain areas of
the brain (17). Several isofonns of the a-receptor have been described, however the
functional significance of this is not known. The receptor is widely ex.pressed and also
binds CORP (2).
Several organ systems are involved in the metabolism of CT. Evidence suggests
that the hormone may be degraded by the kidneys. liver, bone, and even the thyroid
gland. However in most studies, the kidney appears to be the important organ for
clearance of IT (17). Cf disappears from plasma in a multi-exponential manner whereby
the half-life of the peptide in blood is only a few minutes (18).
The primary biologic effect of cr is to inhibit osteoclastic bone resorption. It
accomplishes this by causing the osteoclast to shrink and decrease its bone-rerorbing
activity and this process is mediated by the Cf-receptor. When bone turnover is
sufficiently high. cr will produce hypocalcemia and hypophosphatemia. Controversial
reports have also suggested that CT might inhibit osteocytes and stimulate osteoblasts
(17). In addition. the presence of CT and its receptor at intracranial sites may qualify Cf
as a neurotransmitter (17).
CT is secreted by several endocrine malignancies and therefore can serve as a
tumor marker for diseases such as medullary thyroid carcinoma. Also. cr levels may be
elevated in severely ill patients. such as those with bum inhalation injury.lOxic shock
syndrome. and pancreatitis (2). Because CT inhibits osteoclastic bone resorption. the
hormone is commonly used as a therapeutic agen!. It is used to treat disorders associated
with excess bone resorption. such as osteoporosis and Paget's disease. Analgesia is a
commonly reponed effect of CT treatment of patients with vertebral crush fractures.
osteolytic metastases. or phantom limb (2). CT has also been reponed to act as an
antiinflammatory agent. to prom04:e fracture and wound healing. to increase the excretion
of uric acid. to be antihypertensive. and to impair glucose tolerance (17).
It was thought for many years that as a hypocalcemic honnone. cr might be
important in controlling plasma calcium. For example. evidence from work with young
pigs suggests that. in the shon term (1-2 hours). the loss ofCf leads to a small but
significOJlt increase in plasma calcium concentration that can be restored to normal by
infusion of porcine CT at the basal rate of secretion (19), and also that CT may be
important in mainlaining the plasma calcium concentration within normallimil..
following a meal (20). However, evidence in humans now suggests that CT may not be
required. The levels of CT in the circulation decrease in response to hypocalcemia and
likewise increase in response to hypercalcemia. yet it is uncertain that these changes in
physiological levels of CT have an important biological effect. When CT is presented at
levels up to 10,000 fold higher than normal, as in those with medullary thyroid
carcinoma, there is no detectable abnormality of calcium or bone homeostasis.
Conversely. the absence of CT as a result of thyroid resection for thyroid cancer. does not
impair calcium or bone homeostasis. Finally, it is important to note that many of the
actions atlributed to CT have been observed as a result of pharmacologiml doses of the
hormone. doses thai far exceed Ihe normal physiological concentrations of the hormone.
While CT has been shown to be important for calcium homeostasis in lower organisms
(such as the fishes), it is possible that the hormone has become vestigial or obsolete in
humans and other mammals. Nonetheless. it is still possible that CT plays a role in
normal calcium homeostasis by protecting me body's calcium stores during times of
calcium stress, such as during pregnancy and lactation, growth, and aging (16). For
example, increased levels of cr might help protect the maternal skeleton against
excessive demineralization during pregnancy and lactation (see seclion 1.4).
CORP, a 37-amino-acid peptide, is the major processed peptide in neurons and
thus fUl'lCtions as a neurotransmitter. CGRP is known to be a potent vasodilator thai
might play an important role in cardiovascular regulation (16). CORP reacts with the Cf-
receptor and like CT, the relevance ofCGRP to skeletal mctabolism is unknown. [t may
be produced locally in the skeletal tissue and exert a local regulatory effect (17). Since
bone is highly vascularized and innervated. it is also quite possible that CGRP plays a
role in nonnal skeletal physiology.
1.4 Calci!Onin's Role in Pregnancy and Lactation
In human pregnancy, serum Cf levels have generally b«:n reported to be higher
than nonpregnant levels and the thyroidal C cells. breast. and placenta have been found to
be sites ofCf synthesis during pregnancy {reviewed in (6)). One postulated role of CT is
that it might protect the matemal skeleton from severe calcium resorption during
pregnancy and lactation. However, an adequate experimental model of CT deficiency
had not previously been created, partly due to the fact thaI extrathyroidal sites of CT
synthesis were not appreciated at the time (reviewed in (6)). For example, in 1975. a
study was done using thyroidectomized rats whose parathyroids had been removed and
transplanted to the thigh muscle. and who were injected with thyroxine to restore the
animals to a euthyroid but CT-deficient condition. [f was found that the thyroidectomized
rats had lower bone, total ash, and total calcium weights than control animals 24 days
after parturition (21). The resulls of this study suggest that Cf protects the skeleton from
excessive resorption thai would olherwise occur in thyroidectomized rats during
pregnancy, since in the absence ofCf. the skeleton lost mineral. However, the results of
this sludy are suspect since thyroid honnone levels and CT levels were not measured
following thyroidectomy to ensure that a euthyroid condition had been attained. III
another sludy, goats were thyroparathyroidectomized, with the par3thyroids auto-
transplanted elsewhere in the animal. and were injected with thyroxine to create an
apparently normocalcemic, euthyroid bUI cr-deficient animal. When fed a calcium
deficient diet, these goats lost more bone mineral by day 60 of laclalion Ihan control
(sham-operated) animals (22) (23). However, this model slill suffers from the fact that
thyroxine, thyroid stimulatory hormone, ionized calcium. PTH. and cr levels were not
measured to confirm that the model truly was what il was designed 10 be. It has nOI been
technically feasible to determine whether this postulated role ofCT is operative during
human pregnancy.
1.5 Calcitonin's Role in Felal-Placental Calcium and Bone Homeostasis
As with adult calcium physiology, Ihe exacl role (if any) of CT in fetal calcium
homeostasis and skeletal metabolism remains to be eSlablished. It has been found, by
radioimmunoassay, that immunoreactive CT can be detected in human felal thyroid
glands as early as week 15 of gestation (24). and that fetal CT levels are maintained at
higher levels than maternal (25) (reviewed in (6». The increased levels of CT in Ihe fetus
may renect increased synthesis, however Ihe metabolism and c1ear3nce of cr have nOl
yel been studied in fetal animals. In addition. evidence in rats suggests thai maternal CT
is not able to cross the placenla (26).
Several studies suggest that CT might playa role in fetal calcium homeostasis.
For example. one study demonstrated that infusing CT antiserum {O felal rats increased
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blood calcium in the fetus after I hour (27). In a study on thyroidectomized sheep which
were injectcd with ~~Ca. the amount of ~~Ca accumulation in fetal skeletons (during week
19 of gestation) was significantly greater in fetuses of sheep thai were supplemented with
thyrax.ine alone than in those supplemented with thyrolline and CT or in control animals
(28). In a similar study on intact fetal sheep, CT was found to reduce PTHrP-mediated
increases in calcium accumulation in the fetal skeleton but CT alone had no significant
effC(:t upon transplacental nux of calcium as measured by the accumulation of '<sCa in the
fetal skeleton after administration of ~~Ca to the mother (29). It was later demonstrated in
sheep that fetal thyroidectomy combined with replacement of thyroxine had no effect on
blood calcium in the fetus (30). Taken together. these studies suggest that CT is not
involved in fetal calcium homeostasis.
1.6 The Growth Plate
The development of fetal bonc is a process which is intimately involved in
calcium metabolism and is very sensitive to disruptions in calcium and bone homeostasis.
In mammals, bone development occurs by a process known as endochondral ossification
which occurs at the growth plate, a specialized tissue that is located at the distal and
prollimal ends of long bones (Figure I). The rote that CT normally plays in the process of
fetal bone development has not yet been determined.
The growth plate controls the extension of long bones through a complex.
sequence of events, which has been described in detail (31). Following mesenchymal cell
condensation, the process begins with the formation of a canilaginous scaffold that is
II
Figure I. Endochondral ossification in the mammalian growth plate. The regions of the
growth plate include the zone of resting canilage, zones of proliferation and maturation,
and a zone of hypertrophic cell canilage. Blood vessels invade the hypertrophic area and
osteoclasts resorb the ossified canilaginous matrix. Osteoblasts derived from the bone
collar replace this matrix with bone. (Adapted from (31»)
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later replaced by bone matrix. The mesenchymal cells then differentiate into collagen
producing cells which proliferate until the shape of the future bone is established. The
cells located at the ccnlre of this structure further differentiate into hypertrophic
chondrocytes. These cells are responsible for synthesizing a canilaginous matrix that
eventually calcifies. Simultaneously, mature hypertrophic chondrocytes undergo
apoptosis, allowing blood vessels to invade the region. and a combination of
multinucleate, matrix resorbing cells. and differentiatcd osteoblasts appear. The
canilaginous matrix is then degraded and is replaced by an osteoblast secreted bone
matrix. This organic matrix later accretes mineral and becomes calcified. mature bone.
Thc only cartilaginous structures which remain when the process is complete are thc
growth plate cartilages located at the two distal ends of the bone (311.
Although the terminology used to describe the various zones of chondrocytes in
the growth plate varies greatly, it is generally accepted that there are four main regions
present. These include a zone of resting cartilage. a zone of proliferating chondrocytes, a
zone of differentiating chondrocytes, and a zone of hypertrophic chondrocytes.
1.7 The Placenta
The fetus and placenta must acquire enough calcium to allow the fetal skeleton to
mineralize and to ensure that the extracellular calcium level is physiologically suitable for
fetal tissues (5). It is possible that maternal hormones innuence the transport of calcium
across the placenta by affecting the level of maternal calcium in circulation as well as by
14
directly affecting the placenta. Any role that cr plays in the transpon of calcium from
mother to fetus has not been established.
The placenta is a temporary organ that joins the mother and fetus and functions to
transfer nUlrients and oxygen from the mother's blood into the blood of the fetus, a.~ well
as allowing the release of carbon dioxide and waste products from the fetus back to the
mother (32), The placenta is different from other organs in that it is formed as a result of
interaction between fetal and maternal tissues within the uterus. The placenta is located
outside the fetal body and is connected by a cord of blood vessels. It is also an organ that
has a limited lifespan and is disposable. Large differences exist between closely related
species due to the fact that the placenta displays a wide variety of structural modifications
(33).
The definitive placenta of most mammals is chorio-allantoic, whereby blood
vessels of the mesodermal outer covering of the allantois form a vascular bridge between
the embryo and the al1-enveloping chorion (33). The human and murine placenta are
structurally and functionally quite similar. For example. the chorio-a1lamoic placenta is
the definitive type for both species. ooth have a placenta that is discoid in shape, and both
placental membrane types are hemochorial (whereby [he maternal blood comes in direct
contact with the chorion). However. the murine placenta differs from the human placenta
in that the murine placenta is hemotrichorial (has three layers of trophoblasts) whereas the
human placenta is hemomonochorial (has one layer of trophoblasts) (34). Due [0 the
functional similarities between the two species. the murine placenta serves as an excellent
experimemai model for study of the human placenta.
The placenta is composed of trophoblaslS. which are the peripheral cells of the
blastocyst that attach the fenilized ovum to the uterine wall and subsequently become the
placenta and membranes that nourish and protect the developing embryo (32).
Labyrinthine (or syncytial) trophoblasts. spongiotrophoblaslS. and giant trophoblasts are
the three types of trophoblasts found in the murine placenta. The bulk of the murine
placenta is made up of the labyrinthine crophoblasts. which are considered to be the
dominant site of maternal-fetal exchange. while the giant trophoblasls invade the decidual
tissue and express several honnooes (35).
The intraplacental yolk sac (IPYS) is a structure located in the rodent placenta
which is often overlooked (Figure 2). The IPYS. which is generally considered to be a
remnant of the primitive yolk sac, is found exclusively in rodent placentas. It is actually a
bilayered membrane that is made up of tall columnar cells on the endothelial side
overlaying fetal vessels and maternal blood spaces at the fetal pole of the placenta (35).
Unlike an incorporated remnant. it actually invades. grows, and expands within the
placenta during the latter half of gestation. always remaining situated between the fetal
and maternal vessels (36) (Figure 3).
The actual mechanisms by which the aclive exchange of calcium occurs across the
placenta are poorly unde~tood. It is thought that calcium diffuses into co.lcium
transponing cells through maternal facing basement membranes, is carried across these
cells by calcium binding proteins, and is then actively expelled at the fetal facing
basement membranes by ea-ATPase (the "calcium pump") (35). While the majority of
calcium is transponed actively. some calcium may pass from maternal to fetal
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Figure 2. The intraplaccntal yolk sac (IPYSj in late gestation. Late in gestation, the yolk
sac is compressed such that it completely lines the uterine cavity that is not in contact
with the placenta and it overlies the dome of the placenta. The yolk sac bilayer that is
overlying the dome oflhe placenta forms finger-like projections into the placenta near the
insenion of the fetal vessels, and these projections are termed the IPYS. (From (35))
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Figure 3. Detailed anatomy of the intraplacemal yolk sac (IPYS). The IPYS is situated
between the fetal and maternal blood spaces. The parietal layer and Reichert's membrane
overlie maternal blood vessels whereas the visceral layer overlies the fetal blood vessels.
The sinus of Duval is located between these layers and fuoctions to communicate with the
yolk sac cavity and the uterine lumen. (From (35)).
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circulations by such processes as vesicular transport. paracellular transport. and simple
diffusion (35). The site of active transport is most likely in !he trophoblast cells and
possibly in the endodenn oflhe lPYS in rodents. These cells are in closest proximity to
!he maternal circulation. and the IPYS cells express particularly high levels of
Ca'"ATPase and calbindin-D... (a calcium binding protein).
1.8 Calcitonin/Calcitonin Gene-Related Peptide Knockout Mouse Model
The purpose of this project was to explore the role that cr plays in fetal-placental
calcium and bone homeostasis. This wa." achieved by studying a cr knockout mouse
model in which the gene for cr has been eliminated. Therefore, any effects in fetal
calcium metabolism seen in this model could be attributed to the loss of the honnone.
Until recently. there had nO{ been an adequate model of experimental cr deficiency
created. as previously described in sections 1.4 and 1.5.
The generation of a cr knockout mouse model by Hoff and others (37) provided a
useful model for detennining the precise role of cr in calcium and bone homeostasis.
More specifically. it provides a fetal model for study that otherwise could not be created
by surgical or pharmacological techniques. Mice deficient in cr were created by
replacing exons 2 through 5 of the mouse cr1 gene with PGKneoBPA (these mice were
not generated in our laboratory and therefore the details of their creation will not be
discussed). Since exons 2 through 5 have been replaced. CGRP has also been knocked
out. and therefore. these mice lack both CT and CGRP. However. for the purposes of this
project, this mouse model will be considered to be simply a CT knockout.
2\
Homozygous null mice for Ihe en gene were generated using standard
techniques. are bom normally, are fertile, and also live a normal lifespan. CT deletion
was confirmed by molecular analysis of homozygous knockouts. as well as through the
absence of immunohistochemical siaining for CT in the thyroid gland of the homozygous
animals. A report of how the loss of the hormone in these mice affects calcium and bone
metabolism in the adult is Ihe subject of a separate report by Hoff that has not yel been
published.
1.9 Projeci Description and Purpose
This project specifically examined the role of CT in fetal-placental calcium and
bone homeoslasis. The previous work of others in this area has been complicaled by the
technical difficulties involved in physiological studies of the fetus. and of creating mice
that are completely CT-deficient. The novel strategy used in these studies was to
compare and contra.o;t the physiological impact on fetal calcium homeostasis of the
selective removal of the CT gene through gene targeting. Homozygous (HOM) CT gene-
deleted mice have complete absence of the gene product, the hormone CT. Wild-type
(WT) mice have bolh copies of the cr gene while heterozygous (HET) mice have one
copy of the cr gene and one copy of the knockoul gene.
HET males and females were mated together to create pregnancies in which WT,
HET, and HOM fetuses were present. The HOM fetuses were compared (phenotypically
and physiologically) to their WT siblings to detelTlline if the felalloss ofCT ha.o; any
impact on the fetus.
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HEr males and HOM females were also mated to generate pregnancies in which
HOM and HET fetuses were present. The HOM fetuses of HOM dams were compared to
their HET siblings and to the fetuses of HET mothers. 10 determine if the maternal loss of
cr has any impact on the fetus.
By observing what happened as a result of the absence of CT in the mother or the
fetus, these studies provided the opponunity to determine what role (if any) cr plays in
normal fetal calcium and bone physiology
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II GENERAL METHODS
2.1 Animal Husbandry
2.1.1 Animals
HET males and females were mated to create pregnancies in which WT, HET. and
HOM fetuses were present. HET males and HOM females were also mated to yield
pregnancies with HET and HOM fetuses. The HET and HOM females were first degree
relatives of each olher. The original homozygous knock-oUI mice were crossed into
Black Swiss mice for several generations. Genolypes of mice were confirmed by
polymerase chain reaction (PeR) of genomic DNA. Animals were maintained in
facilities operated by Animal Care Services of Memorial University of Newfoundland, in
accordance with the Canadian Council on Animal Care (CCAC). All protocols were
approved by the InslilUlionai Animal Care Committee ((ACe).
2.1.2 TimedMatings
HET and HOM females were mated overnight Wilh HET males. The geslalional
day 0.5 was marked by the presence of a vaginal mucous plug on lhe morning following
mating. The normal mouse gestation period is 19 days and fetuses of gestalional ages of
usually 18.5 days were slUdied. Fetuses of day 17.5 gestational age were utilized for
placentalcalciuffilransfersludies.
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2.2 Genotyping
2.2.1 DNA Extraction
To genotype fetuses. the tail was clipped and placed in 500 J.lI of lysis buffer (100
mM Tris-HC1. pH 8.0 I 500 mM EDTA. pH 8.0 I 0.2% SDSI200 mM NaCI) containing
[00 IJglml of proteinase K and were incubated at 55 "C for 12-24 hours. In brief.
genomic DNA was precipitated with isopropanol. resuspended in water. extracted with
phenol-chloroform. followed by precipitation by ethanol. The DNA was generally
resuspended in 501J1 of pH 8.0 Tris-EDTA buffer (10 mM Tris and I mM EDTAl and 1.5
III of DNA was subsequently used for peR. The DNA extraction procedure is outlined in
detail in the Appendix.
2.2.2 Polymerase Chain Reaction
Oenotyping was achieved by PeR using primers specific to the CT gene sequence
in a single-tube 36-cycle PeR reaction. A three primer system was utilized and included
primers for the retained portion of the wr allele (CT- [). a deleted portion of the WT
allele (CT·3). and the inserted neomycin sequence (CT-N) (Figure4Al. These primers
utilized the specific sequences: CAG GAT CAA GAO TCA ceo CT (CT-I), GOA GCC
TOC ocr CCA OCG AA (IT-3), and GGT OOA TOT GOA ATG TOT GC (CT-N)
(from OlBCO BRL. Burlington. Ontario).
PeR results were analyzed using gel electrophoresis. A 2% agarose gel was made
(2 g agarose, 10 ml of lOx TAE \Tris-Acetic Acid-EDTAI. and 90 ml water), was
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Figure 4. Genotyping by polymerase chain reaction (PeR). 4(A) A schematic of the
normal and targeted CT allele with approximate locations of primers indicated. Mouse
genotype wa<; tested using two PeR reactions and 3 different primers. CT-l is a primer to
CT exon I, which is present in normal and knockout animals. CT-3 isa reverse: primer in
intron I and CT-N is a reverse primer in the neomycin gene. 4(8) A schematic of the
PeR product electrophoresed on an agarose gel. to demonstrate the typical results of a
genotyping experiment. CT-I and CT-3 primers are paired to detect the wild-type allele
whereby the PeR product is approximately 250 base pairs. CT· I and CT·N primers are
paired to detect the knockout (homozygous) allele whereby the PeR product is
approximately 150 base pairs (B). Wild-type =WT, homozygous =HOM, and
heterozygous = HET.
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microwaved for two minutes, 6j.l1 of ethidium bromide was added, and was poured into a
gel tray. 10 j.ll of each PCR product (combined wilh 2 pi of Orange G loadingdyel was
added 10 a well in the gel. The samples were run on the gel in an electrophoresis chamber
at 200 volts for 25-30 minutes in 700ml of IxTAE buffer. Gel results were documented
using a Multi Image Light Cabinet and Chemi Imager-4000 soflware package from Alpha
Innotech Corporation (Canberra-Packard Canada Ltd.. Montreal, Quebec). Genotypes
were subsequently determined from the photographs. WT produces a 250 bp band, HOM
produces alSO bp band, while HET produces both 250 bp and 150 bp bands (showing
both the WT and HOM alleles) (Figure 48).
2.3 Data Collection
2.3.1 Litter Sizes
At the time of each cesarian section (day 17.5 or 18.5 of gestation), the number of
fetuses present were counted to determine the liller size. This number would be higher
than the litter sizes observed 6-24 hours after binh, due to normal loss of pups in the
period after birth.
2.3.2 Whole Blood and Serum Collection
On day 18.5 of pregnancy, dams were anesthestized by isonurane (Janssen.
Toronto, Ontario) inhalation and whole blood was collected from the heart using a 26
gauge needle and syring~. Pregnant dams were euthanized by rapid cervical dislocation.
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The fetuses were quickly removed (to minimize changes in malernal/fetal blood
chemistry) by cesarian section. leaving the uterus intact. Each individual fetus was
removed from its amniotic sac. and the left carotid and jugular vessels were transected
using a razor blade. For serum collection, approximately 40-75 IJI of whole blood was
collected from each fetus into plain capillary lUbeS. The samples were then separated by
centrifugation and serum was stored at -20 "C until used for study.
2.3.3 Placental Perfusion
Placenta~ were obtained for study following placental perfusion with
paraformaldehyde.to minimize mRNA or protein degradation which could occur during
the fixation and processing of the RNase and protease-rich placental tissues. In brief,
dams (at day 185 of pregnancy) were anaesthetized with isonurane and a thoracotomy
was performed. A 23 gauge needle was inserted into the left ventricle of the heart and the
right ventricle was cut open to allow fordrainage. 10 ml of Ix PBS (phosphate buffered
saline) was slowly perfused into the heart. After most of me blood was nushed out, 10 ml
of 4% paraformaldehyde was perfused into the heart. Following perfusion, the placentas
were removed and placed in 10% formalin. and subsequently processed, embedded in
paraffin, cut into 5 IJm sections, and placed onto slides (using standard techniques). A
detailed procedure is provided in the Appendix. The placental genotype was determined
from the fetal tail DNA.
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2.3.4 Tissue Preparation
Fresh tissue samples were obtained from fetuses of HET x HET matings thai
delivered at day 18.5 of gestation. For histology. fetuses were fixed in 10% buffered
formalin. Following fixation, fetal tibias and femurs were removed from hind limbs,
processed. embedded in paraffin and sectioned at 5 ~m thick. using standard techniques.
2.3.5 Amniotic Auid Collection
Amniotic fluid is very scanty and viscous on day 18.5 of gestation, therefore.
amniotic fluid was collected from day 16.5 and 17.5 fetuses. Each pregnant dam was
killed by cervical dislocation and the intact uterus was removed by cesarian section. Each
gestational sac was subsequently lanced. and 40-75 ,.d of fluid was collected into
heparinized capillary tubes. The amniotic fluid was then decanted into storage tubes and
frozen at -20 "C. Fetal tail clippings were taken for subsequent genotyping.
2.4 Placental Calcium Transfer
The rate of placental calcium transpon was measured in accordance with the
procedure previously developed by KovacHt al. (9). On day 17.5 of gestation, pregnant
dams were anesthestized by isoflurane inhalation. These mice were then given 50 ~ei of
,sea and 50 lJCi of 11Cr·EDTA (in 0.9% saline) by intracardiac injection (the tOlal volume
injected was 100 Ill). IICr_EDTA crosses the placenta by diffusion only and was used as
a blood diffusional marker to control for blood flow differences between placentas. The
dams were euthanized five minutes after the injection by cervical dislocation. A five
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minute time point was used to minimize the possibility of calcium backflux from fetus to
mother. The intact uterus was removed from the mouse by cesarian section and each
fetus was removed from its amniotic sac. The tail of each fetus was clipped for
subsequent genotyping. and each fetus was placed in a lest tube and asphyxiated. The
amount of ~ICr activity was measured using a gamma counter and the fetuses were then
solubilized with 10 ml of Scintigest (Fisher Scientific, New Jersey) at 55°C for 48 hours
and then were vortexed to disperse the tissues. When the fetuses were fully solubilized.
10 ml of scintillation fluid was added. along with 5 drops of glacial acetic acid (to
minimize bioluminescence and chemoluminescence). The vials were then shielded from
light and equilibrated iO room tcmperature for 12-24 hours. A beta counter was used to
measure ·~Ca activity and the ratio of'~Cal"Cr activity was calculated for each fetus.
2.5 Mineral assays
2.5.1 Ionized calcium
Whole blood was collected from the tail vein of dams on day 18.5 of pregnancy
into 50 J.lI heparinized capillary tubes which were capped and subsequently placed on ice.
Fetal blood was normally collected on day 18.5 gestation so as to maximize the amount
thai could be collected. The pregnant mouse was euthanized by rapid cervical dislocation
and the fetuses were quickly removed by cesarian section (to minimize changes in
maternal/fetal blood chemistry), leaving the uterus intact. Each individual fetus was
removed from its amniotic sac, and the left carotid and jugular vessels were transected
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using a razor blade. Approximately 30-50 J.II of whole blood was collected into 50 J.I1
heparinized capillary tubes, a volume sufficient for one ionized calcium measurement.
The capillary tubes were capped and immediately placed on ice and the order that each
fetus collected in the litter was recorded. The tail of each fetus was subsequently clipped,
placed in lysis buffer. whereby DNA was later extracted for PeR gen()(yping. Each fetal
and maternal blood sample was analyzed for the ionized calcium and pH on a
CffiAiComing 634 Ca-'pH analyser (with a measurement range of 0.20 mmollL to 5.00
mmoVL for Ca'" and 6.00 to 8.00 for pH). The raw ionized calcium values were used for
analysis.
2.5.2 Serum Magnesium
The magnesium content of fetal serum was determined using a Magnesium Kit
from Sigma Diagnostics (51. Louis, MO). This procedure was carried ou( as directed in
the package inselt(Appendix).
2.5.3 Serum Phosphorus
The inorganic phosphorus content of fetal serum was delennined using an
Inorganic Phosphorus Kit from Sigma Diagnostics (Sl. Louis. MO). This procedure was
carried ou[ as directed in the package insen (Appendix).
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2.5.4 Fetal Ash Weights
Each genotyped fetus was weighed. placed in a crucible and reduced to ash in a
Thermolyne Type F62700 furnace for 24 hours. 1be ash was then dusted onto weighing
paper and each sample was weighed. The ash weight of each fetus renects the total
mineral content of the fetal skeleton.
2.5.5 Flame Atomic Absorption Spectroscopy
Fetal skeletal calcium and magnesium content were analyzed using atomic
absorption spectroscopy. 253 III of ultra pure nitric acid was added to fetal ash collected
in sample vials. The samples were then allowed to dissolve at room temperature for 3
days. 10 ml of distilled water was added to each vial. dilutions were made, and samples
were run in duplicate on a Perkin-Elmer 2380 Atomic Absorption Specuometer. Results
were convened to mglg of ash.
2.6 Calciotropic Honnone Assays
2.6.1 PTH ELISA
The PTHcontenl offeta! serum was determined using a Rat 1·J4lntact PTH
ELISA (Enzyme-Linked ImmunoSorbent Assay) Kit from Immutopics (San Clemente,
CA). The procedure was camed out as outlined in the kit protocol (Appendix).
However, in cases where sample serum volumes were less than 25 1-11, samples were
diluted with apglml Standard.
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2.6.2 Rat cr IRMA
The cr content of maternal and fetal serum was determined using a Rat CT
IRMA (Immunoradiometric Assay) Kit from Immutopics (San Clemente. CA). The
procedure was carried OUI as oudined in the kil prolocol (Appendix). However. [00 ",I of
pooled serum plus 100~1 of Sample Diluent reagent was used for each fetal sample. No
pooling was required for maternal serum samples.
2.7 Skeletal and Placental Histology and Morphology
2.7.[ Insitll Hybridization
For in situ hybridization on fetal placental seclions. "S-riboprobes for cr.
calbindin-O'l'< and COl-ATPase were prepared. For in sim hybridization on fetal bone, JlS_
riboprobes for collagen I, collagen II, collagen X, cartilage matrix protein (CMP).
histone4, alkaline phosphatase. osteocalcin. 92-kO gelatinase. PTHrP. collagenase-3, and
osteoponlin were prepared. The specific probes used were generated from the
appropriated cONAs whereby the generation of labelled slfands which are
complementary to Ihe cDNA are antisense probes. The detailed in si/ll hybridizalion
procedure is provided in the Appendix. Essentially. the procedure involves lhe
linearization and purificalion of plasrnids. labelling of riboprobes. prehybridization
trealment of slides. application of the probe cocktail, posthybridizction washes,
autoradiography, staining. and photography. Bright field and/or dark field microscopy
were used to examine results whereby comparisons were made between WT and HOM
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mice from the same lilters and specimens had been treated under the same experimental
conditions. Results wen: interpreled based on the intensity and location of mRNA
expression.
2.7.2 Immunohistochemistry
Immunohistochemistry was performed on 5 fJm placental sections using two
panicular antibodies: anti·CT (DAKO. Denmark) was used at I:200 dilution and anti-Cf-
receptor (counesy of P. Wookey. UniversityofMelboume. Australia) was used at 1:500
dilution. Both antibodies were used with secondary antibody. ABC reagent. and DAB·
Tris-peroxidase kits obtained from Vector (Burlinglon. Ontario). Slides containing
placental sections were incubated in 1.0% HPl in melhanol (to inactivate endogenous
peroxidases) for 30 minules at room temperature. and incubaled with 100 1..11 of blocking
serum for 20 minutes (to saturate cellular Fe receptors). Following this. slides were
incubated with [00 fJ.1 oflhe primary antibody at4 "Covemight for the CT antibody and
for one hour at room temperature for Ihe CTR antibody. Next. 100 fJ.1 of biotinylated
secondary antibody was applied to each section for 30 minutes, followed by incubation
wilh DAB-Tris·peroxidase for 10 minutes and counter-stained with Contrast Red
(Kirkegard and Perry Laboralories. Gaithersburg. Maryland) for 5 minutes and
subsequently washed. dehydrated, and mounted with Permount ( Fisher Scientific
Company. Fair Lawn. New Jersey) and a coverslip was applied. Staining intensity was
determined using bright field microscopy in a blind manner whereby the genotype was
not known. These results were confirrtted on at least 2 separate tillers.
J5
2.7.3 Alizarin Red Sand Alcian Blue Staining:
Day 18.5 fetuses were fixed in 95% ethanol for at least 5 days. Sk.in. viscera. and
adipose tissue were removed within 2 hours of death. A detailed protocol is provided in
the Appendix. In brier. the fetuses were placed in acetone for at least 2 days in order to
remove fat and keep the specimen finn, stained for 3 days in staining solution at 37 ·C.
and washed in water. Following this, fetuses were cleared in 1% aqueous KOH for 1248
hours andsubsequenlly in 20%. 50%, and 80% glycerol I 1% aqueous KOH solutions.
Specimens were stored in 100% glycerin. As a result of this procedure, alizarin red
stained bone red and alcian blue stained cartilage blue.
2.7.4 Von Kossa's Staining
This procedure is described in detail in the Appendix. In brief. fetal bone tissue
sections were deparaffinized, rehydrated in decreasing concentrations of ethanol (100%,
100%,95%, and 75%) and then equilibrated in distilled water. The sections were then
placed in I% aqueous silver nitrate solution and exposed to strong light for a 45 minute
period. The sections were then washed three times in distilled water, treated for 5
minutes with 2.5% sodium thiosulfate and washed with distilled water again.
Subsequently, the sections were counter-stained for 2 minutes with methyl green, rinsed
in l-bUianolthree times, dehydrated, and mounted with Pennounl.
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2.8 Statistical Analysis
Data were analyzed usingSYSTAT 5.2.1 for Maclnlosh (SYSTAT, Evanslon.
IL.). ANOVA (analysis of variance) was used for all data analysis. Two<-tailed
probabilities are reponed and all data are presented as mean ± SE. P < 0.05 was
considered statistically significant.
For sludies with results that may have been influenced by non-genolypic factors.
including numbers of feluses in the litter and size of feluses, Ihe data were nonnalized.
The mean HET result for each litter was set Oil 100%, and HOM and WT results were
expressed as a percemage of this HET mean. This method was used 10 nonnalize values
among the pups of each liuer so that comparisons may be made belween differemlitters.
Results were nonnalized to the HET mean since the HET genotype occurs at Iwice the
frequency of either the WT or HOM. corresponding to the Mendelian Talio of 1:2: I.
Since HET fefUses make up 50% of the total fetuses, the normalized value is more stable.
Also, HET fetuses have both WT and HOM alleles and therefore should present an
inlermediate phenotype.
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III RESULTS
3.1 Maternal Effects of CT Deletion
We measured liner size, marcOla! ionized calcium levels, and compared pregnant
and nonpregnant HET and HOM females. in order to determine if there were any
maternal effects of cr delelion.
HET males and females were mated to create pregnancies in which WT, HEr. and
HOM (elUses were presem. HET males and HOM females were also mated to yield
pregnancies with HET and HOM feluses. The HET and HOM females were first degree
relatives of each other in order [0 ensure thai comparisons are made between mice of the
same genetic background. The in II/ero liner size of HOM females was significantly
lower than that of HET females (7,89 ± 0.39 pups (28 tilters] vs. 9.12 :t 0.31 pups [43
lilters]. respectively; p=O.OI7) (Figure 5).
We measured maternal serum ionized calcium levels and compared pregnant and
nonpregnant HET and HOM females. Maternal blood was obtained from tail veins on
day 18.5 of gestation. Maternal calcium levels were 1.28 ~0.02 mmolll in HET and 1.29
~ 0.02 mmolll in HOM dams (p=NS. and no different from the corresponding
nonpregnant maternal values) (Figure 6).
In summary, maternal loss of CT affected litter size but had no effect on maternal
blood calcium.
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Figure 5. Comparison of in Iltuo fetal number (mean ±SE) of HET and HOM dams.
The number of observations is indicated in parentheses.
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Figure 6. Ionized calcium levels (mean ± SE) in pregnant ve~us non-pregnant HET and
HOM female mice (p=NS). The number of observations is indicated in parentheses.
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3.2 Placental Calcium Transpon
The fetus and placenla must oblain sufficient calcium to mineralize the skeleton,
and maintain an extra-cellular level of calcium that is physiologically appropriate for felal
lissues. Maternal hannones might influence fetal-placental calcium transpon by raising
or lowering the ambient malernal calcium level and by direct effects on lhe placenla. We
measured the rales of calcium transpon across the placenta to Ihe fetuses of both HET and
HOM dams. Placental calcium Iransfer was assessed by administering >lCa and IICr (as a
diffusional marker) to the pregnant dam, by intracardiac injection, on day 17.5 gestation.
The amount of 'lCa transferred to each fetus within 5 minules (nonnalized by "Cr) did
nOl differ among feluses ofHET dams (96.01 ±8.24% in HOM fetuses. 101.29 ±6.08% in
HET fetuses, and 102.37 ±7.81% in WT fetuses: p=O.83l (Figure 7A), No significant
differences belween HET and HOM feluses of HOM dams were found (99.83 ::4.47%
and 94.93 ::4.30% respectively; p=O.43) (Figure 78).
Thus. it appears that neither felal nor matemal loss of cr affects lhe rate of
Iranspon of calcium across the placenta from mother to fetus.
3,3 Mineral Physiology
Ninety-nine percent of the body's calcium and mosl of its magnesium resides in
the skeleton. We measured the content of lhese minerals in the skeletons of fetuses of
HET and HOM dams. We also measured serum levels of calcium, magnesium. and
phosphorous because the regulation of calcium metabolism is often linked 10 phosphorous
metabolism. and 10 a lesser extent. magnesium metabolism.
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Figure 7. Placental calcium transport of·$Ca and $ICr-EDTA in fetuses of HET (Al and
HOM (B) dams. The ratio of~Ca I'ICr activity was determined 5 minUies after maternal
adminislration of the isolopes. Results were normalized to the mean HET value for each
litter (p=NSl. The number of observations is indicated in parentheses.
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We measured ionized calcium levels of WT, HET. and HOM fetuses of HET
dams. Todetennine if maternal loss ofer had any effect on fetal calcium, we also
measured ionized calcium of fetuses of HOM dams. As well. in all mammals that have
been studied, the fetal blood calcium (both total and ionized) is maintained at a higher
level than in the maternal circulation and is believed to result, in part, from the active
transport of calcium across the placenta. However, the physiological importance of fetal
hypercalcemia is not known. Thus, we compared the amount of ionized calcium in
maternal circulation to that in fetal circulation in these knockout mice to detennine
whether the loss ofCT has any effect on the fetal-maternal calcium gradient Fetal blood
was collected by carotid/jugular transection. on day 18.5 of gestation (one day before
expected birth). HOM fetuses exhibited a nonnal fetal-maternal calcium gradient with a
fetal ionized calcium that did not differ from their HET or WT siblings, and did not differ
by the mother's genotype ([.59 :to.02 mmolll in HOM (etuses from HOM dams vs. 1.63
:t 0.01 mmolll in HOM (etuses from HET dam~, p=NSl (Figure 8).
Magnesium levels were measured in serum of fetuses of both HET and HOM
dams. Serum magnesium levels of HOM fetuses of HET dams were significantly lower
than thai of Iheir WT siblings (0.58 :t 0.10 mmollL vs. 1.08 ± 0.1 0 mmol/L, respectively;
p<O.OO6) (Figure 9Al. Also, HOM fetuses of HOM dams had significantly lower serum
magnesium levels than theif HET littennates (0.86 ± 0.03 mmol/L vs. 1.01 ± 0.03
mmoVL, respectively; p<O.O(4) (Figure 98). Serum phosphorous levels did not differ
among fetuses of HET dams (1.64 :dUO mmol/L in HOM fetuses, 2.42 :to.2l mmollL in
HET fetuses, and 2.36 ±.30 mmoVL in WT fetuses: p=O.1 I) (Figure lOA) and HOM dams
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Figure 8. Ionized calcium levels (mean ± SE) of fetuses from HET (A) and HOM (B)
dams (p=NS). The number of observations is indicated in parentheses.
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Figure 9. Serum magnesium levels in fetuses of HET (A) and HOM (Bl dams. Fetal
serum magnesium was significantly reduced (p=O.0063) in HOM fetuses of HET dams, as
compared 10 WT liltermates. Serum magnesium was significamly reduced (p=O.OO37) in
HOM fetuses of HOM dams. compared 10 HET littermates. The number of observalions
is indicated in paremheses.
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Figure 10. Serum phosphorus levels in fetuses of HET (Al and HOM (8) dams (p=NSl.
The number of observalions is indicated in parentheses.
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(2.02 ±O.15 mmollL in HOM fetuses ys. 2.28 ~.15 mmollL in HETfetuses: p=O.24)
(Figure lOB). HOM serum phosphorus levels trended lower but were not significantly
different.
We measured the gross skeletal mineral present at the end of gestation by
determining the ash weighls of fetuses. Fetuses of both HET and HOM dams were ashed
at 500~C for a period of 24 hours. The ash weights (If fetu~s were calculated and
nonnalized to Ihe mean heterozygote value for each litter. No differences were found in
ash weights of HOM fetuses of HET dams compared 10 HET and WI linennates (102.40
%2.95% in HOM fetuses, 100.05 %2.00% in HET fetuses, and 97.66 :t3.31 % in WT
fetuses: p=O.57) (Figure IlA). We also compared ash weights of HOM 10 HET fetuses of
HOM dams. No significant differences were found (100.13 :1.78% in HOM fetuses liS.
100.02 %:2.[9%: p=O.97) (Figure liB).
The fetal ash was funher analyzed by atomic absorption spectroscopy to more
specifically quantify the amount of calcium and magnesium present and thereby
determine whelher Ihe loss of cr affected the tOlal skeletal calcium and magnesium
content. Results were calculated in mglg of ash and normalized to the mean heterozygote
value for each litter. Total skeletal calcium of HOM feluses of HET dams did not differ
from their HET and WT siblings (97.59 ±4.09% in HOM fetuses, 101102 %2.8990 in HET
fetuses, and 101.89 :4.72% in wr fetuses; p=O.78) (Figure 12A). TOlal skeletal calcium
of HOM fetuses of HOM dams did not differ from their HET litterrnates (101.96 : 1.17%
in HOM fetuses liS. 99.99 :1.42% in HET fetuses; p=O.29) (Figure 12B). Total skeletal
magnesium of HOM fetuses of HET dams did not differ from their siblings (97.65
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Figure 11. Gross skeletal mineral present at {he end of gestation is represented by the
relative ash weights of fetuses of HET (A) and HOM (B) dams. Results are expressed as
a percentage of the HET mean (p=NS). The number of observations is indicated in
parentheses.
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Figure 12. Detennination of skeletal calcium content by atomic absorption spectroscopy
in fetuses of HET (A) and HOM (B) dams. Results were calculated in mglg of ash and
nonnalized to the mean HET value for each litter (p=NS). The nllmbcrof observations is
indicated in parentheses.
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:1:.3.59% in HOM fetuses, 100.07 ±2.54% in HET fetuses. and 100.36%4.15% in WT
fetuses; p=O.84) (Figure I3A). However. a trend was found belween the tOlal skeletal
magnesium of HOM fetuses compared to HET fetuses (93.3Ch 2.58% and 100.08 %
2.13% respeclively: p=O.0527) (Figure 138).
In summary, loss of fela! or malernal cr caused a reduction in the concentration
of magnesium in the feta! circulalian and possibly in the fetal skeleton. However, fela!
serum calcium and phosphorus. and skelelal calcium contenl were nOt affecled.
3.4 The Felal Skeleton
Fela! bones were studied since bone is a compartment which is intimately
involved in calcium melabolism and it mineralizes in late geslation. Therefore, disruption
of calcium homeaslasis and especially placental calcium Iransfer could result in altered
skeletal development, altered skeletal mineral content, or altered gene expression in the
growth plate.
The gross morphology and mineralization oflhe felal skeleton were studied using
a1cian blue and alizarin red S staining. This procedure allows us to visually observe the
morphology of the skeleton, as well as Ihe relative amount and distribution of cartilage
and mineralized tissue thai is present. Using this procedure, the soft tissues become
transparenl and Ihe entire skeleton (cartilaginous and mineralized portions) can be
visualized. Alizarin red stains mineralized tissue (such as bone) red whereas alcian blue
stains cartilage blue. No apparent differences were found when comparing the amount
and distribution of bone and cartilage staining of HOM fetuses to their WT liUennates,
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Figure 13. Determination of skeletal magnesium content by :lIomic absorption
spectroscopy in fetuses of HET (A) and HOM (B) dams. Results were calculaled in mglg
of ash and normalized to the mean HET value for each liller. Skeletal magnesium content
in HOM fetuses of HOM dams was reduced by 7% (p=O.0527). There were no
differences found between fetuses of HET dams. The number of observations is indicated
in parentheses.
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nor did there appear to be any morphological differences between the fetal skeletons, such
as the length and shape of the long bones (Figure 14).
The amount of bone mineral present in the growth plates of fetal bones was
further studied using the von Kossa method. In this method. mineral is blackened by
silver phosphate and silver carbon:ue complexes. This method detects inorganic
phosphates and carbonates. however, since calcium is the only cation that binds to
inorganic phosphate and carbonate anions in living tissues. this method is also considered
to be an indirect but specific test for the presence of calcium (3S) (39). Using this
method. the amount of mineral present in HOM fetal bones did not differ from that of
their WT siblings (Figure 15).
In situ hybridization was performed on fetal bone sections to detennine whether
the expression of important markers of bone development and cell type are altered in the
absence of CT. mRNA expression of markers for the various cellular regions of the
growth plate were studied. A detailed list of the mRNAs that were studied is provided in
Table I. however only results for those probes which produced clear and consistent
results are reported. We examined expression of collagen II (a proliferating chondrocyte
marker). CMP (a differentiating chondrocyte marker), and collagen X (a hypertrophic
chondrocyte marker). We also examined the expression of the osteoblast markers
collagen I and osteopomin. Based on fetal bone in situ hybridization results. it appears
that there were no differences in the expression of collagen Il (Figure 16), CMP (Figure
17), collagen X (Figure 18), collagen I (Figure 19). or osteopontin (Figure 20). when
comparing HOM fetuses to their WT littermates. For results where the mRNA signal is
61
Figure 14. Gross morphology and mineralization of fetal skeleton. Alizarin red S and
a1cian blue staining was used to compare HOM fetuses to WT Iiuennates. Alizarin red S
stains mineralized tissue (such as bone) red whereas alcian blue stains the cartilage blue.
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Figure 15. Detennination ofmincral contcnt of fetal bones. von Kossa's staining was
used to compare the amount of mineral present in fetal bone sections of HOM fetuses (8)
as compared to WT (A) Iittennates. Minemlizcd bone is blackened by silver deposition
and osteoid is countcrstained with Methyl Green. Pictures shown are bright field images
and the various cellular regions of the growth plate are indicated. Normal intensity of
staining (black) is seen in HOM fetal femur sections as compared to WT sections.
Calibration bars in each panel indicate 50 ~m.
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Table 1: Specificily of mRNAs used for in sitll hybridizalion studies on fetal bone
tissue seclions
Collagen I bone
Collagen II bone
Collagen X bone
Collagenase-3 bone
OSleopontin bone
Osteocalcin bone
Cartilage malrix prolein bone
Histone 4 bone
Alkaline phosphatase bone
92-kDGelatinase bone
PTHrP bone
OSleoblasls
Proliferating chondrocyles
Hypertrophic chondrocytes
OSleoblasts
OSleoblasts
OSleoblasts
Differentiatingchondrocylcs
Hypertrophic chondrocytes
Osteoblasts
Osteoclasts
Proliferalin£ chondrocvtes
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Figure 16. In silll hybridization for Collagen II mRNA in fetal tibia sections. Pictures
shown are bright field images of sections counterstained with hematoxylin and eosin.
Normal dislribution and intensity of Collagen n mRNA signal is seen in HOM fetuses (8)
compared to WT littermates (A), The signal (silver grain deposition), which is
represented by black, is present throughout the canilaginous cells of the growth plate.
Calibration bars in each panel indicate 50 I!m.
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A
Figure 17. In situ hybridization for cartilage matrix protein (CMP) mRNA in fetallibia
seclions. Paired bright field (A and B) and dark field (C and 0) images of the same
seclions (counterstained with hematoxylin and eosin) are shown. Nonnal distribution and
intensity of CMP mRNA signal is seen in HOM fetuses (8 and 0) compared to wr
Iiuennates (A and C). The signal (silver grain deposition). which is represemed by black
in bright field images and while in dark field images. is presem Ihroughoutthe growth
plate and is most intense in the zone of differentiating chondrocyles. Calibration bars in
each panel indicate50j.1m.
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Figure 18. In situ hybridization for Collagen X mRNA in fetal femur sections. Pictures
shown are bright field images of sections countcrstained with hematoxylin and eosin.
Normal distribution and intensity of Collagen X mRNA signal is seen in HOM fetuses
(B) compared to WT littermates (A). The signal (silver grain deposition). represented by
black, is intense in the zone of hypenrophic chondrocytes. Calibration bars in each panel
indicate50lJm.
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Figure 19. In siw hybridization for Collagen [ mRNA in fetal femur sections. Pictures
shown are bright field images of sections counterstained with hematoxylin and eosin.
Nonnal distribution and intensity of Collagen [ mRNA signal is seen in HOM fetuses (8)
compared [0 WT !itlermates (A). The signal (silver gr,lin deposition). is present in the
periosteum and bone shaft. Calibration bars in each panel indicate 50 Ilm.
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Figure 20. fn siw hybridization for osteopontin mRNA in fetal tibia sections. Paired
bright field (A and B) and dark field (C and D) images of the same sections
(counterstainetJ with hematoxylin and eosin) are shown. Normal distribution and
inlensity of osteoponlin mRNA signal is seen in HOM fetuses (8 and 0) compared to WT
liuennates (A and C). The signal (silver grain deposition). which is represented by black
in bright field images and white in dark field images. is present in the periosteum and
bone shaft. Calibration bars in each panel indicate 50 IJrn.
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imense. only bright field images are shown. However. for those results where the signal
is less imense. paired bright field and dark field images are shown. Results of osteoclast
markers have not been reported and therefore require further examination.
Based on these results. it appears that loss of fetal cr does not impact the
measured parameters of skeletal morphology or development. mineral levels. or gene
activity in the growth plate.
3.5 Calciotropic Hormones
We were interested in measuring calciotropic hormones in serum, including those
hormones which are known to be important in calcium and bone metabolism. such as
PTH. calcitrio!. and CT. The purpose of this was to determine whether the loss of er
causes an up-regulation or down-regulation of other hormones. For example. it may be
possible that another hormone is compensating for the loss ofer. and that this might be
apparent through an increase or decrease in the circulating level of another calciotropic
hormone. However. our efforts to measure these hormones were limited by the
availability of serum and appropriate assays.
PTH is one of the principal physiological regulators of calcium homeostasis for
humans and all terrestrial vertebrates. Therefore. we mea.<>ured serum PTH levels in
fetuses of heterozygous dams using a Rat Intact PTH 1-34 ELISA kit from Immutopics.
Serum PTH levels of HOM fetuses (12.60 ± 2.21 pglml) did not differ from their HET
and WT siblings (12.9\ ±1.56 pglml and 18.6\ ±2.22 pglml. respectively: p=O.09) (Figure
21). For several of the WT serum samples the volumes were less than the required 25 IJ\
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Figure 21. Serum PTH levels (mean ± SEJ in fetuses ofHET dams (ANOVA p=O.09J.
The number of observations is indicated in parentheses.
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and were therefore diluted wilh 0 pglml Standard solution. This dilution of the specimens
may account for the non-significantly increased PTH levels observed in the WT fetuses.
Serum Cf levels were measured in HET and HOM dams and in Iheir fetuses using
a Rat cr IRMA Kit from Immutopics. HET dams had a mean serum cr level of 95.02
±10.30pglml as compared to 7.16 ±16.82 pglml in HOM dams (p=O.OO16) (Figure 22).
Assuming thalCf is nOi present in HOM dams. the value of7.16 pglml must represent a
true zero and the threshold of detectability for CT in mice. The stated assay sensitivity is
0.6 pglml with this k.it in rats. However. the threshold of sensitivity has not been
detennined in mice.
Fetal serum CT analysis revealed a step-wise dose dependent response by
genotype in fetuses ofHET dams (WT: 125.62tI6.11 pglml > HET: 48.86 tl2.30 pglmJ
> HOM: 7.37 ±J4.21 pglml; p=O.OOOO4) (Figure 23AJ. Similar results were found in
fetuses of HOM dams (HET: 41.11 ±5.98 pglml > HOM: 9.42 ±3.71 pglml: p=O.OOO4)
(Figure 238). The cr levels of HET and HOM fetuses respectively do not vary by the
mothers genotype (Figure 23). This is consistent with the hypothesis that CT does nOI
cross the placenta. Furthermore, the CT levels of HOM dams and HOM fetuses are all
identical. This is consistent with the hypothesis that the level of -8 pglmL represents a
true zero for this assay in mouse serum.
3.6 Molecular Mechanisms of Placental Calcium Transport
Placentas were studied in order to determine what compensatory effects on
cellular morphology may occur as a consequence of the loss ofCf. Thus, such elements
80
Figure 22. Serum CT levels (mean ± SE) in HET and HOM dams (p=O.OOI6). The
number of observations is indicated in parentheses.
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Figure 23. Serum CT levels (mean ± SE} in felUses of HET (A) and HOM (8) dams. A
step-wise decrease is seen. according to genotype. in feluses of both HET and HOM
dams. HET fetal CT levels are the same between HET and HOM dams and HOM fetal
CT levels are the same between HET and HOM dams. The number of observations is
indicated in parentheses.
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as the size. appearance and distribution of trophoblasts as well as the presence of the
IPYS were examined. Since the placenta is the sile of calcium transfer. it was also
imponant to detennine whether the cells and factors they express. which are involved in
this transfer. are altered in CT gene-deleted mice. The site of active transpon is likely to
be in the trophoblast cells and in the endodenn of the IPYS in rodents. These cells are in
closest proximity 10 the maternal circulation and the IPYS cells express particularly high
levels ofCa- ATPase (the "calcium pump") and high levels of calbindin-D",,(a calcium-
binding protein). Calbindin-D"" is also known to be an IPYS marker. Therefore. we
examined the level of expression of calbindin·D"" and Ca- ATPase in placentas of CT
gene-deleted fetuses compared to their WT siblings. Based on placental ill siw
hybridization results it appears that there are no differences in the intensity or location of
mRNA expression of calbindin-D"" (Figure 24) and Ca- ATPase (Figure 25). nor did
there appear to be any gross differences in cellular appearance or structure. In addition. a
preliminary sWdy on placental weights of fetuses of HET dams suggests that there are no
dirrerences among fetuses (0.0736 ~.OO89 g in HOM fetuses (n=2). 0.0838 ±OJJ052 g in
HET fetuses (n=6). and 0.0917 ±O.OOS2 g in wr fetuses (n=6): p=O.24).
3.7 Calcitonin and the Calcitonin-Receptor in the Placenta
Contradictory evidence exists on whether or not the CT and Cf-receptor genes arc
actually expressed in the placenta. Funhermore. if CT and its receptor are not normally
present in the placenta. that could explain why we see lillie effC(:t upon loss of the CT
gene. The CT knockout placenta represents an ideal model to detennine the specificity of
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Figure 24. /n siw hybridizalion for calbindin-D"" mRNA expression in 5 11m placental
sections. Pictures shown are bright field images of sections counterstained with
hematoxylin and eosin. Normal distribution and intensity of calbindin-D... mRNA signal
is seen in HOM fetuses (B) compared to WT liUermates (A). Intense signal (silver grain
deposition). which is represented by black. is seen in the IPYS and light signal is seen in
trophoblasts. The appearance and distribution of trophoblasts and IPYS also appear to be
normal in HOM fetuses. Calibration bars in each panel indicate 50 fJm.
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Figure 25. In silu hybridization for Ca-ATPase mRNA expression in 5 11m placental
sections. Pictures shown are bright field images of sections counterstained with
hematoxylin and eosin. Normal distribution and intensity ofCa'"ATPase mRNA signal is
seen in HOM fetuses (B) compared to WT littermates (A). Intense signal, (silver grain
deposition) which is represented by black, is seen in the IPYS and less intense signal is
seen in Irophoblasts. The appearance and distribution of lrophoblasls and IPYS also
appear to be normal in HOM fetuses. Calibration bars in each panel indicate 50 11m.
"

CT mRNA and immune signals, and determine if it is truly present or not. Therefore. in
.Iitu hybridization and immunohistochemistry were performed to detennine if these genes
are expressed in placental tissue and where they are expressed. CT mRNA was diffusely
expressed throughout the WT placenta. in the intraplacental yolk sac and in the
labyrinthine trophoblasts (Figure 26). A signal was not detected in the extra placental
yolk sac (EPYS). In contrast. CT mRNA was not detected in HOM placentas. thereby
confinning the specificity of the signal detected in the WT placenta. Similar results were
found by immunohistochemistry, using aCT antibody (Figure 27). Antibody to CT-
receptor revealed moderate, diffuse staining in the IPYS and labyrinthine trophoblasts
(Figure 28). The most intense staining was seen in the EPYS.
These results provide evidence that CT and the CT-receptor are indeed present in
the placenta. Being located in the placenta. CT would be expected to play some role in
placental function.
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Figure 26. In situ hybridization for CT mRNA expression in 5 IJm placenlal sections.
Paired bright field (A and C) and dark field (B and DJ images of the same sections
(counterstained with hematoxylin and eosin) are shown. CT mRNA signal is present
throughout labyrinthine trophoblasts (T) and both layers of the IPYS (arrows) in WT
placental sections (A and B). There is no signal detected in the EPYS (E).
Corresponding images from HOM placental sections (C and Dj show no signal. The
signal (silver grain deposition) is represenled by black in bright field images and white in
dark field images. Calibration ban; in each panel indicale 50 Jim.
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Figure 27. Placental immunohistochemistry using cr primary antibody. cr
immunoreactivity is present in the IPYS in WT (AI as compared to HOM placenta (B).
Bright field images are shown and the calibration bar in each panel indicates 50 ~m.
Arrows indicate IPYS.
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Figure 28. Immunohistochemistry using cr-receptor primary antibody on WT placental
s«:tions (B). The adjacent control section (A) received identical treatment to the
experimental s«:tions except for the use of the primary antibody. cr-receptor
immunoreactivity is present at low levels throughout the labyrinthine trophoblasts (n and
the IPYS (arrows), and at more intense levels in the EPYS (E). Bright field images are
shown and the calibration bar in each panel indicates 50 JIm. Arrows indicate IPYS.
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IV DISCUSSION
In these studies we measured several parameters of calcium and bone metabolism
to detennine whether the loss of the cr gene affected the fetal-placental unit. In this
way. we expected to detennine whether cr was critically required for any aspect of
normal fetal-placental calcium homeostasis and skelelal development. We examined Ihe
maternal effects of cr deletion, placental caldum transport. as well as aspects of fetal
mineral physiology and skelelal development. We also looked at the molecular
mechanisms involved in placental calcium transport. assayed calciotropic hormones. and
examined the presence ofCT and its receptor in the placenta. We have demonstraled that
homozygous deletion of the CT gene did eliminate cr but did not affect maternal or fetal
ionized calcium levels. the rate of felal-placental calcium lransfer, serum phosphorus
levels, or the amount of mineral present in each felal skeleton. It also did not affect fetal
serum PTH levels. the gross skelelal morphology. the expression of important bone
markers. or calbindin-D~"or Ca'" ATPase expression in placentallissue. However. we
did find that maternal loss of cr resulted in a reduction in litter size and that maternal and
felal loss of cr resulted in a reduclion in the concentralion of magnesium in Ihe fetal
circulation and possibly in the felal skeleton. It is important to point out that since a
Cf/CORP knockout model was actually studied. the results demonstrate that lack of both
hormones had little effect. In addition. our SlUdies confirm that the genes for cr and the
Cf-receptor are located in the murine placenta. although the funclion of cr and its
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receptor in the placenta is unclear since no abnormality of placental structure or function
has been demonstrated.
Early in the study we noticed that HOM dams often had smaller lilters than their
HET siblings. We confirmed that HOM dams had significantly smaller in utero litter
sizes than HET dams. Our data clearly show that CT deficiency will result in a lower
liuer size. but cann()( distinguish whether this is due to an impairment in oocyte number.
oocyte release. fenilization. implanlation. or survival through early embryonic
development to the fetal stage. However. we do know that since we did not see a
selective reduction in the number of HOM fetuses. that it is the loss of maternal cr that is
affecting the litter size. Our finding is not without precedent. cr has been shown to be
involved in the implantation of the mammalian embryo to the uterine wall. Zhu and
others (40) found that the administration of antisense CT oligodeoxynucleotides into the
lumen of the preimplantation rat uterus resulted in a severe impairment in embryonic
implantation. They therefore proposed that cr plays a crucial role in the uterus during
blastocyst implantation. In addition. it was demonstrated that CT expression in the
human endometrium is temporarily restricted to the mid·secretory phase of the cycle.
which closely overlaps with the putative window of implantation (41). Thus, one
possible interpretation of our findings is that a loss of CT reduces the likelihood of
implantation of the embryo to the uterus, resulting in fewer embryos actually succeeding
in implantation. Although reduced implantation may be a factor. further study is needed
in order to rule out the effects of the lack of CT on Other stages of development. from
oocyte onward, as previously mentioned.
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The notion that cr might playa role in magnesium regulation appean to be a
novel finding. However, since calcium. phosphorus. and magnesium regulation are inter-
related, it is not that surprising a result. II is possible that cr may innuence the transpon
of magnesium across the placenta from the mother to the fetus: unfonunalely, an
appropriate magnesium isolope (affordable and with a sufficiently long half-life) to use to
study this possibility is not available. In order to determine how cr affects magnesium,
it would be relevant to study the effects ofeT on magnesium handling by the fetal
kidney, which could be studied indirectly by measuring the magnesium content in
amniotic fluid. Amniotic fluid is largely composed of fetal urine and is accepted 10 be an
indirect measure of renal function. For example. if there is less magnesium crossing the
placenta to Ihe fetus we would expect to see a decrease in the magnesium content of the
amniotic fluid. Whereas if the felal kidneys are actually wasting magnesium, we would
expect to see an increase in the magnesiumcomem of the in the amniotic fluid. Another
possibility is that eT is influencing another factor which in tum is affecling magnesium
regulation. One method to confinn that IT is directly involved in magnesium
homeostasis would be to treat HOM fetuses with cr in lItuO 10 see if magnesium levels
(in serum and bone) return 10 nonnal.
Based on the measured parameters, it appears that cr gene-deletion does not
affect the skeletal morphology, net mineral accretion, or gene activity in the growth plate.
However, some of these methods are semi-quanlitative and there may be differences that
we are unable to detect using such methods. For example, we looked at gene expression
but did not examine cell size, number or detailed microscopic appearance. It is also
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possible that other markers which we have not studied might show differences. In
addition, precise measurements of fetal bones should be taken to determine how the loss
of cr affects bone struelure and size. It is very imporl:lOt that such studies be done since
it is possible that we are overlooking small details ordifferel'lUS between the feral
skeletons.
Our results confirm that cr has indeed been ablated in the knockout mice. The
results revealed a step-wise decrease in CT levels by genotype with WT having the
highest level of CT, HOM having no CT. and HET having an intermediate level. This
indicates that one copy of the cr gene is not sufficient to ensure nonnallevels of CT.
Similar intermediate effects of a HET state have previously been reponed in Hoxa3
knockout mice (these mice lack parathyroid glands) whereby PTH levels revealed a
dosing effect according to genotype (7). The results also suppon previous findings that
cr does not cross the placenta (26) since HOM fetuses had the same low level of CT
regardless of whether the darn produced cr (HEr dam) or not (HOM dam). However,
the kit thai was used for the Cf assay was designed for detection ofCT in rats. not mice.
We found HOM fetal and maternal CT results to be in the range of :tpproximately 8
pglml. This is most likely the threshold of detection for cr in mice (using this kit).
confirming that cr is not present in the HOM mice (adults and fetuses). On the other
hand, if this value is not a true zero, then it would have to be explained how HOM mice
have low levels of CT present in serum. For example, is CT being tmnsferred from HET
fetuses to HOM d:uns and from there to HOM felUses ill utero, thereby accounting for
similarly low levels of CT in HOM fetuses and dams? This could be tested by HOM x
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HOM matings which would produce only HOM fetuses and eliminate any possible fetal .....
materna!..... fetal cr transfer. Another possibility is that there could be another gene
which produces cr. however this is highly unlikely given that the mouse genome has
been fully sequenced and no cr homologous genes have been reponed.
We were interested in examining other calciotropic honnones known to be
involved in calcium in bone homeoslasis. Despite the fact that loss of cr did not
significantly affect fetal serum PTH levels. it may still be that some other honnone is
compensating for the loss of CT. Therefore, funher measurements of honnones such as
PTHrP, calcilriol, and sex steroids such as estrogen in the knockout mice would be an
asset to the study. These honnones have not yet becn measured simply due to the
limiting factor of the availability of sufficient fetal serum.
Placental in sim hybridization results imply that there are no differences in the
intensity or location of expression of caibindin·O." and Ca" ATPase in HOM placentas
and that the cellular and structural appearance of the placentas also appear to be normal.
However. there are still aspects which could be looked at in more detail. since our
observations are more qualitative. For example, although preliminary results suggest that
there are no placental weight differences among fetuses of HET dams, a larger
investi~ation is required. In addition, an in depth examination of the size and number of
trophoblasts in plocentaltissue. as well as measurements of the volume of IPYS in
placental tissue could be taken. The expression of other important placental markers
could also be examined.
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Identifying the location of calciotropic genes in lhe placenta. will help determine
the pathway involved in placental calcium transpon and provide insight into which genes
are involved in the process. The localization of expression of many calciO!ropic genes
has either not been reponed or many of these repons used outdated methods or antibodies
whose specificity would not be considered adequate by modem standards. Contradic!ory
evidence has existed on whether or nO! the cr gene is expressed in the placenta. For
example. it had been reponed that IT is expressed in the rat and human placenta (42)
(43). However, Ihese results arc inconclusive partly due 10 problems wilh antibody
specificity and the studies did not identify the specific cells thai appeared to secrete cr.
In contrast. several studies have demonslrated the presence of the cr-receptor in Ihe
placenta. For example, using radiolabeled-eT binding studies, the cr-receptor was
found to be located in the syncytiotrophoblast brush border (facing the mother) as well as
in the basal plasma membrane (facing the fetus) of the human placenta (44). Our studies
show that cr and the cr-receptor are present in the labyrinthine trophoblasts and IPYS
of the placenla.
We examined several indices of calcium and bone metabolism in this sludy. II
appears thai the complele loss of eilher maternal or fetal cr did not affect the majority of
these parameters. However, the resulls do imply that there is a relationship between the
loss of IT and magnesium regulation. They also suppon previous findings that CT is
involved in the implantation of the mammalian embryo 10 Ihe U1erine wall. Taken as a
whole. these results suggest Ihat cr is nol e~sential for the survival and developmenl of
the fetus nor for any parameter of calcium metabolism thai we have measured thus far.
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Such negative results are consistent with the theory that CT is a vestigial hormone in
mammals that has no physiological role in calcium homeostasis.
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APPENDlX
DNA EXTRAl.TION FRO"-I TISSUES
I. Put tissue (e.g. tail lip) in Eppendorftubes containing 0.5 mllysis buffer. Buffer is
stored at room temperature: proleinase K is added shortly before use.
2. Incubale overnighl at 55 °C on shaker.
3. Ne:u morning. shake horizontally by hand for 210 3 minutes. and spin on micro
centrifuge for 10 minutes at maximum speed 10 precipitate hair (not necessary for
felalsamples!).
4. Pour supernatant into fresh Eppendorf tubes containing 0.5 ml isopropanol. and invert
to precipitate DNA.
5. Pick DNA up with small pipette lips and put it into Eppendorftubes containing 0.5 ml
water.
6. Shake by hand for 5 minutes to dissolve DNA into a viscous solution.
7. Add 0.5 ml of phenollchlorofonnlisoamyl alcohol (100: 100: 1) and shake vigorously
for approx. I min. A lurbid. milky solution should result.
8. Spin 2 minutes 011 maximum speed in micro centrifuge.
9. Carefully aspirate the supernalanl and place it in fresh Eppendorf lubeS. Add I mlof
25: I EtOH:NaOAc solution. Invert several times until DNA comes out of solution.
10. Spin for 10 minutes 011 maximum speed to precipitate DNA. A liny pellet should be
seen.
II. Discard the supernatant by pouring it off. then add I ml of 70% EtOH.
12. Pour off the EtOH and dry Ihe pellet by leaving Ihe Eppendorf tube inverted, or place
il in a vacuum centrifuge (Speed-Vac).
13. Resuspend DNA pellet in 50fJL TE (Tris·EDTAl and put in warm water bath for at
least 20 minutes to resuspend. A viscous solution should result. Add more TE if too
viscous.
14. Allow the DNA 10 go into solution overnight before using (can be used within 20 min
for PeR). Store at 4 °C.
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PERFUSION OF ADULT MICE
Fill a 20 mlsyringe with PBS and another with 4~ PFA (parafonnaJdehyde) or
IQli, formalin (or other fixatives) @4-C. Attach n.gauge butterfly needle 10
PBS syringe.
2. Anesthetize mouse. lay mouse on its b3ck. Open thorax. CUI cattfully through
ribcage and diaphragm to access the hean. Work. fast but do not tear any major
vessels.
3. Insen the 23g buuerfly needle into the left \'entricle (it may be helpful to hold the
needle in the left ventricle with forceps). Cut open the right ventricle for drninage.
allowing the lit PBS to be slowly but constantly perfused into the hean. If
perfusion is working. liver. spleen and kidneys should tum grayish-white.
4. After most of the blood has been flushed out. unscrew PBS syringe from the
butterfly and replace it with the PFA or fonnalin syringe. Slowly pt;:rfuse the
mouse: with about 20 ml of fixative. A muscle tremor will appear in the limbs and
tail. and by the end of the fixative perfusion the mouse: will be stin. If perfusion is
not successful at this point. the procedure should be abandoned.
5. Following perfusion. dissect out organs and tissues. transfer into labeled vials
filled with fix:llive and store at4 0c.
113
APPENDlX
MAGNESIUM KIT
(SIGMA Diagnostks Procedure No. S9S)
I!u&<Dl>:
Magnesium Base Reagent (Cat. No. 595-4)
2x25mL
Magnesium Color Reagent (Cat. No. 595-6)
50mL
Magnesium Standard Solution (Cal. No. 595-2)
10 mL (2 mEqIL)
Wear lab coat. gloves. etc. Reagents are harmful(color). corrosive (basel. and an irritant
(standard).
1'Ill«dJIw
I. Tum on Spectrophotometer. Set absorbance to 520 nm
2. Prepare Magnesium Assay Solution by mixing equal volumes of Magnesium Base
Reagent and Magnesium Color Reagent. Magnesium Standard Solution is ready-to-
use. Can mix all 100 ml in a bottle: store in refrigerator - Assay Solution is stable for
at least 4 days.
3. Label 3 cuvcttes - I blank and 2 standards.
4. Add 1.0 mL Assay Solution to each cuvette
5. To blank cuvette add 10 III dHP
6. To each standard cuvette add 10 III Magnesium Standard Solution
7. To each test cuvette. add 1.0 mL Assay Solution and 10 III of your sample
8. Read and record absorbance at 520 nm of lest and standards vs. blank as reference
(color is stable for at least 30 minutes)
9. To detennine magnesium concentration. perfonn the following calculations:
Magnesium (mEqIL) =~x 2.0 ICOll(entration of Magnesium Standard Sol\ltionl
Astandatd
To convert to mgldl. multiply your answer from the above equation by 1.216
To convert results into mmollL. multiply your mgldL answer by 0.41
Example: standard = 0.170
test =0.140
Magnesium (mEqIL) = Q,HQ x 2.0 = 1.6
0.170
Magnesium (mgldLl = \.6 x 1.216= 1.946
Magnesium (mmollL) = 1.946 x 0.41 = .798
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Background or test:
Various dye techniques have been used for magnesium determination. For this purpose,
the metallochromic dye, calmagitc, 1-[I-hydroxy-4-methyl-2-phenylazo]-2-naphthol-4-
sulfonic acid, offers one of the best approaches. The Sigma technique is ba.~d on this
reaction and proceeds as follow:
CaJmagite + Magnesium -----. Calmagite-Magnesium Complex
The unmetal1ized form of lhe dye in the presence of magnesium forms a pink
magnesium-calmagite complex thaI can be measured at 520 nm
[I'
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INORGANIC PHOSPHORUS KIT
(SIGMA Diagnoslics Procedure No. J60.UV)
Il<a&ral;.
Phosphorus Reagent (Cat. No. 360-3)
(Ammonium molybdate. 0.40 mmol/L. in sulfuric acid with surfactant)
Store Phosphorus Reagent in refrigerntor (2-8°C),
Wear lab coat. gloves. etc. Reagents are hannful(color), corrosive (base). and an irritant
(standard).
E1:lI<Ilbu:<;.
I. Tum on Spectrophotometer. Set absorbance to 340 nm
2. Label 3 cuvettes - I blank and 2 standards.
3. To blank cuvette add 1.0mL Phosphorus Reagent and O.OlmL of water
4. To each standard cuvette add 1.0mL Phosphorus Reagent and O.OlmL
CalciumlPhosphorus Standard (Catalogue No. 360-5)
5. To each test cuvette. add 1.0 mL Phosphorus Reagent and O.OlmL of test specimen
6. Read and record absorbance of STANDARD and TEST at 340nm vs BLANK as a
reference. Absorbances are stable for at least 15 minutes at room temperature.
7. To detennine inorganic phosphorus concentration. perfonn the following calculations:
Inorganic Phosphorus (mgldL) = A..I.ESI.....-- X 5
A STANDARD
To convert results into 51 units. multiply inorganic phosphorus value (mgldLl by
0.323.
Example: A TEST = 0.350
A STANDARD =0.480
Inorganic Phosphorus (mgldL) =lLl.lll,'
0.480
=3.6
Inorganic Phosphorus (mmol/Ll = 3.6 x 0.323 = 1.16 mmollL
Principle:
Inorganic Phosphorus + H)SO. +Ammonium Molybdate
•Unreduced Phosphomolybdate complex
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The reaction of inorganic phosphorus with ammonium molybdate in the p~nce of
sulfuric acid (H:SO". produces an unreduced phosphomolybda,(e comple.... The
absorbance of this comple... 3.( 340nm is dirttlly proponiOfl4I to the inorganic phosphorus
concentration.
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RAT INTACf PTH ELISA KIT
Immutopics. Inc. 96 test kit (store at 2-8"C)
Cat.# 60-2500
I. Make sure all reagents are at room temperature
2. Make sure plate washer and plate reader are available for the times when they will be
needed
3. Reconstitute standards with deionized water - must sit for at lea.'il 20 minutes (with
occasional gentle swirling)
~ apglml with 2.0 ml water
~ other 5 standards and 2 controls with 1.0 ml water
~ make an extra standard between 0 and 25 (half the 25 pglml) since fetal PTH should
give low values
~ refer to vial labels for exact concentrations!
4. Make working antibody solution (equal amounts of Rat ITH Biotinylated Antibody
and Rat PTH HRPConjugated Antibody. Mix well. stable for 7 days if stored in light-
protected container at 2-8"C). ONLY make volume required for immediate use.
5. Place a sufficient number of Streptavidin Coated Strips in a holder to run ITH
standards. controis and unknown samples
6. Pipet 25~1 of standard. control. or sample into the designated or mapped well. Fl'ffze
the nmainin. standards and controls as soon as possible aRer use
7. Pipet lOOJ,J.I of the Working Antibody Solution into each well
8. Cover the plate with one plate sealer. then cover with aluminum foil to avoid
exposure to light
9. Incubate plate at room temperature for 3 hours on a horizontal rotor (180-220 RPM)
10. Dilute wash concentrate during this incubation period (add 190ml deionized water to
lOmI wash concentrate. Store diluted wash solution at room temperature)
II. Remove the aluminum foil and plate sealer. Aspirate the contents of each well. Wash
each well five times by dispensing 350~1 of working wash solution into each well and
then completely aspirating the contents. Allernatively, an automated mic:rotiter
plate washer can be used - need extra wash solution if using automated washer
12. Pipet 150J,11 of ELISA HRP Substrate into each of the wells
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13. Re-cover the plate with the plate sealer and aluminum foil. Incubate at room
temperature for 30 minutes on a horizontal rotor (180-220 RPM)
14. Remove the aluminum foil and plme sealer. Read the absorbance at 595nrn within 5
minutes in a micrOliter plate reader against the 0 pglml Standard wells as a blank
15. Immediately pipet 10(lJ1I of ELISA Stop Solution into each of the wells. Mix gently
16. Read the absorbance at 450nm within 10 minutes in the microtiter plate reader against
a blank of 250Ji1 of distilled or deionized water
Note: if wavelength correction is available, set the instmment to dual wavelength
measurement at 450nm with background wavelength correction set at 595nm
7 It is recommended that all standards. controls, and samples be assayed in duplicate
7 Store light sensitive reagents (HRP Conjugated Antibody, Working Antibody
Solution, and ELISA HRP Substrate) in the original amber bollies or other suitable
container which is protected from the light
7 Slore any unused Streptavidin Coaled Strips in the resealable aluminum pouch with
desiccant
7 The sample and all reagents should be pipetted carefully to prevent bubbles in wells
7 Sequence and timing of each reagent addition is important as both Ihe immunological
and enzymatic reactions are in kinetic modes. The use of an aUlomated microliter
plate washer is strongly recommended. All pipeuing and washing steps should be
performed such that the timing is as consistent as possible
7 Freeze/thaw of plasma samples may accelerllle clot formation. These samples must be
centrifuged and decanted prior to assay to remove all particulate material which can
cause random high non-specific binding on well surface
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RAT CA.LCITONIN IRMA KIT
Immutopics.Inc.
Cat.# 50-5000
Test Principle:
The Rat Calcitonin IRMA Kit is a two-site immunoradiometric assay (IRMA) for the
measurement of rat calcitonin in serum, plasma or cell culture media. Two different
antibodies to rat calcitonin are used in the assay. A monoclonal antibody is immobilized
onto plastic beads 10 capture the calcitonin molecules and an affinity purified polyclonal
goat antibody is radiolabeled for detection.
A sample containing rat calcitonin is incubated simultaneously with an antibody coated
bead and the '1!I labeled antibody. Calcitonin contained in the sample is immunologically
bound by the immobilized antibody and the radiolabeled antibody 10 fonn a "sandwich"
complex:
Bead/Anli-Rat Calcitonin---Rat Calcitonin--- '1!( Anti-Rat Calcitonin
Allhe end of the incubation period. the bead is washed to remove any unbound labeled
antibody and other components. The radioactivity bound to the bead is then measured in
a gamma counter. The radioactivity of lhe antibody complex bound to the bead is directly
proponionalto the amount of rat calcitonin in the sample. A standard curve is generated
by plotting Ihe CPM standard on logarithmic scales. The concentration of rat calcitonin
in the samples is detennined direclly from this curve.
Assay Procedure:
I. Pipet 200~ of standard. control or sample into appropriately labeled tubes
2. Pipet 100~ of 1~1 Labeled Rat Calcitonin Antibody into aJitubes.
3. Vonex all tubes.
4. Using forceps or appropriate bead dispenser. add one bead to each tube. Tilt lube
rack to approximately a 30 degree angle to prevent splashing. Cover tube rack with
Parafilmorequivalent.
5. Incubate tubes at room temperature for 18 to 24 hours.
6. Aspirate the contents of each tube. Wash the beads three times by dispensing 2 mL of
wash solution into each tube and then completely aspirating the contents.
7. Count each tube in a gamma coumer for one minute and record the counts.
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Calculation of Results:
The standard curve is generated using the rat calcitonin standards contained in the kit.
Refer to individual vial labels for exact concentrations. Generale the curve as follows:
I, Calculate the average CPM for each pair of duplicate assay tubes.
2. Sublr:lCt the average CPM of the 0 pglmL Standard from all other average CPMs to
obtain corrected CPM.
3, The standard curve is generated by plotting the corrected CPM of each standard level
on the ordinate against the standard concentralion on the abscissa using log-log paper.
Appropriate computer assiSled data reduction programs may also be used for
calculation of roll calcitonin results.
The rat calcitonin concenlration of the controls and samples are read directly from the
slandard curve using their respective corrected CPM. Samples having a correcled CPM
between the 0 pglmL Standard and Ihe nellt highest standard should be calculated by the
formula:
Value of unknown Corrected CPM (unkngwn) II Value of the 200l Std.
Corrected CPM (2noJ Std.)
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IN SITU HYBRIDIZATION
IN SiTU HYBRIDIZATION: PURIFYING LINEARIZED PLASMID
Increase volume to 200 1-11 water.
2. Add 200 ,.d phenoVchlorofonn. Vortex vigorously 10 !iCconds.
J. Centrifuge for 2 minutes. collect supernatant into a fresh tube.
4. Add [/10 volume 3 M NaOAc and 2 [/2 volume EtOH.
5. Freeze on dry ice at least 5 min to precipitate DNA.
6. Centrifuge at 12.000g for 15 min in cold room.
7. Pour off supernatant.
8. Add 500 1-1170 % EtOH. Invert several times.
9. Vortex. cemrifuge 10 min to ensure pellet adheres to bottom.
10. Pour off supernatant and SpeedVac until pellets are dry (approximately 20
minutes).
II. Resuspend in 10!-l[ water (depending on original concentration!) and store at-
20°C.
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IN SITU HYBRIDIZATION: LABELING RIBOPROBES
Linearize the plasmid containing probe of interest with appropriate restriction
enzymes. USUally linearize 10 jJg DNA. Check the linearization on an agarose
gel. then purify by phenol/chloroform extraction and ethanol precipitation. Store
at _20°C in water at IIJg/fJl.
2. Label the probe using the SP6ff7 transcription kit (Promega).
Reaction mixture is:
5x transcription buffer
lOOmMDIT
rATP
.cTP
oGTP
3SS·UTP (125 fJCi)·
RNasin
linearized plasmid (I IJg)
appropriate polymerase
2.00'1
1.00'1
O.5jJl
a.5jJl
a.sjJl
3.00'1
0.50'1
1.01J1
1.00'1
·dry up 10 10 IJI of original solution of 35S_UTP (#NEG 039H. New England Nuclear) by
Speed-Vac beforehand. Dissolve the pellet with 3 fJI water.
lncubate [ hr @ 37 "C (waterbath). Then add another 1.0 jJl of polymerase and
incubate for an additional I hr @ 37°C.
4. Add 0.5 jJl RNasin
0.51-11 DNase
Incubate 15 min @ 37"C.
5. Add 0.5 M EDTA
5,NTE
(5x NTE= 100 roM Tris pH 7.5. 500 roM NaCl. 50 mM EDTA)
6. Remove unincorporated nucleotides with NucTrap column (Stratagene H400702).
Apply 70 1-11 of Ix NTE to top of resin bed and push through column. Discard the eluanl.
Apply sample prepared above (70 IJ[) and push through the column. collecting Ihe eluant.
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Apply 70 pi of Ill: NTE 3.gain 3.J1d push rhrough. adding this elu:uJ( to the previous
fraction.
7. Coum the radioactivity of I pi probe in 10 ml scintillation fluid in 3. scintillation
coomer. Counts should be 0.5-1.5 II 106 cpmlpl.
8. StoreprOOeat·70OC.
9. (fnecessary. check the integrity ofthc probe by running our 5 pi ofme probe on a
denaturing acryl3.J11ide gel. Dry the gel and apply to film for autoradiography.
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IN SITU HYBRIDIZATION: PREHYBRlDIZATION TREATMENT
All solutions are based on 600 ml volumes and dishes.
Put slides in slide wanner for 15 min to dry them and melt paraffin.
2. Prepare 4% parafonnaldehyde (PFA) in PBS:
540 ml waler (boil before adding other ingredients!)
600 J,ll 10 N NaOH
24 g paraformaldehyde powder
Allow it to go into solution. Add 60 ml lOx PBS. Then add 600 J,ll diethylpyrocarbonate
(DEPC) (k.ept in fridge). Add 2OOJ,l1 12 N HCI and check. pH (it should be -7.5 by filter
strip check). Add more He! or 10 N NaOH to adjust pH as needed. Then let solution
cool down and pour into a dish.
3. Deparaffinize and rehydrate the sections.
a. xylene 5min
b. xylene 5min
c. xylene 5min
d. 100% EtOH I min
e. 95% EtOH I min
f. 70% EtOH I min
g. PBS I min
4. 4% parafonnaldehyde (PFA) in PBS for 15 min
5. PBS for 5 min
6. 10 J,lglml proteinase K in PBS @ 37°C for 15 min
(600 J,ll of 10 mglml proteinase K in 600 ml PBS)
7. 4% PFA in PBS for 10 min (reuse from step 4).
8. PBS for 5 min.
9. 0.2 N HCl for 10 min.
(10 ml 12 N Hel in 600 ml water)
10. PBS for 5 min.
II. 0.1 M triethanolamine (pH 7.5) for 2 min.
125
APPENDIX
(7.8 ml TEA plus 7 ml water in a 15 m[ Falcon tube: vortex, then add to 600 ml
waler)
12. 0.25% acetic anhydride for 10 min.
(1.8 ml acetic anhydride in 5 ml water: shake vigorously in a 50m! Falcon tube.
then pour over the slides in the TEA MAKE DIRECTLY BEFORE USE!)
13. PBS for 5 min,
14. 70% EtOH for 5 min.
15. 95% EtOH fod min.
[6. Air-dry. Apply diluted probe 10 sections and apply coverslips as described.
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IN SITU HYBRIDIZATION: APPLYING PROBE COCKTAIL
BYBRlDIZATlON SOLUTION
Gnal CQoceDlratjon
SO% fonnamide
IOmM Tris-HCI (pH 7.6)
200 ~g/ml tRNA
Ix [)eRhardt's solution
10% dextran sulfate
600mM NaC!
025%SPS <pHSffi
fina] volume
SI"'k
Sml(IOO%)
lOO"'(IMl
100 ,I (20,gI,"l
200l!1CSOx)
2 m! (lO%l
1.25 ml (SM)
250,,1(10%)
10mi
(or 50 m!
25001
lOO,l
lOO'"
1000,"
10m!
6ml
125m!
50001
When preparing hybridization solution, dissolve dextran sulfme in waler and NOlet
before adding other items. Store hybridization solution @ _20°C in 2 rot aliquolS.
Prior to use. add 5% vlv of I M dithiothreitol (OIT) to solution and add labeled
prol>e. Always use fresh aliquols of hybridization solution and OIT.
2. Dilute probe in hybridization mixture with OIT to a final concentration of - .5 x
107 cpmlml. Or. can usually simply use 5% probe vlv if probe COil", is ~ I x 106
cpm. E.g. for 1401-11 probe, use 71J1 OTI. 7 III probe and 126 III hybridization
juice. Or use digoKigenin-labeled probe at 1% by volume and detect by alkaline
phosphatase or other methods.
3, Denature diluted probe in 85 °C water bath for at least 5 min. Leave probe in
water bath until ready to add to sections.
4, After prehybridization and EtOH drying of slides, apply probes to sections. Use a
volume of 50-100 fJl per slide, depending on the amounl of tissue per slide,
5, Cover slides with parafilm coverslips. taking care to delicately press out any
bubbles.
6, Incubate overnight @ 55 °C in a humidity chamber containing 50% fonnamide-
soaked wicks,
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IN SITU HYBRIDIZAnON: POST HYBRIDIZAnON WASHES
Incubale slides in 5x SSC @ 50 °e for 10 min. Prewarm the waterbath 10 prevent
dextran from precipilating. Genlly remove coverslips from lhc slides.
2. 2x sse I 50% formami<te @ 50 ~e for 30 min.
3. TNE(IO mM Tris·HCI, pH 7.6; 500 roM NaCl: 1 mM EDTAl@3JOefor 10
min.
4. 10 Ilglml RNase A in TNE @ 37 °C fOf 30 min.
(100 III of20mglml solution RNase A per 200 ml TNEl
5. TNE @ ]7 °C for 10 min.
6. 2)( sse @ 50 °e for 20 min.
7. O.h SSC @ 50 ·e for 20 min.
8. 0.2)( sse @ 50 °e for 20 min.
9. 70% EtOH for 5 min.
10. 70% EIOH for 5 min
II. 95% EtOH for 5 min.
12. Air-dry.
13. AUloradiogl1lphy as described.
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AUTORADIOGRAPHY
EQUIPMENT
Darkroom with: safelight conditions (Wratten In)
temp 18-20 °C, reI. humidity 40-50%
water bath @43°C
NTB-2 emulsion. a1iquoled
2% glycerol in water
dipping jar or slide mailers for photographic emulsion
dryingplale
desiccant
slide boxes (Iight-tight, or with aluminum foil 10 wrap)
Kodalcdeveloper
Kodak fixer
7Ql1,& 100% ethanol
Place slides in an autoradiography cassetle with suitable x-ray film. Expose ill
room temperalure overnight or longer, and develop. Use the resulting film
exposure as a gauge for delermining the duralion of liquid emulsion exposure
(roughly 4x as long to achieve the same level of signal as observed on film).
2. Aliquot the solid NTB-2 emulsion (Kodak) into eight 20 ml brown light-tight
containers (Nalgene. Fisher). wrap in aluminum foil and store in a black bag at4
°C (ideally in the darkroom). Emulsion may be stoced 4 monlhs or less.
3. Under safelight conditions. melt ;m aliquOl: of NTB·2 at 43°C for 45-60 min.
Prewarm 10 mlof2% glycerol in water in a 15 ml rube during this lime. SCi upa
large (I liter) beaker with 600 rnl water @ 43 °Co which will hold the dipping jar.
4. Place: the dipping jar in the beaker of warm water. Pour the melted emulsion into
the dipping jar, ;md then slowly pour in the prewumed 2% glycerol in water
(avoid causing bubbles). Dip a clean slide in and out several times 10 mix the
emulsion with the 2% glycerol in water. Check that emulsion is bubble-free by
examining the slide for an even coating. Repeat this until the bubbles are
removed, if needed.
5. Nut dip the experimenlal slides. allowing each to drain venically for 2 sec .. and
biOi the end on paper. Immediately place the slide invened (marking side down)
on a slide rack 10 dry.
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6. When the lasl of lhe slides~ dipped. Ir.lnsfer slides to slide boxes containing a
sachet of deslccanl. Be careful 10 place the boxes on edge so Ihat the slides will
remain invened.
7. Wrap each slide box with three sheets of aluminum foil. ~al with tape. and place
at 4 (Ie. If possible. place al room lemperature ovemighllo avoid rapid cooling.
then move to 4 ·C.
8. After a suilable interval of exposure lime (determined in step I above) remove !he
box of slides from the cold room and wann 10 room lemperature (> I hr.)
9. Under safelight condilions in a darkroom. transfer the slides into a slide rack and
pass through the following:
Kodak DEKTOL developer 2 min
(dissolve 17 g per 250 ml water)
b. distilled water 15sec
Kodak fixer 5 min
(dissolve 45 g per 250 ml water)
d. dislilled water 5 min
dry in dust-free atmosphere
Prepare fresh developer each day. Use alleast 5 ml of each reagent per slide.
10. Tum lights on.
II. Air-dry.
12. Proceed with Hemaloxylin and eosin staining.
hematoxylin
water
eosin
70%EIOH
8O%EIOH
90% EIOH
100% EtOH
100% EtOH
xylene
xylene
xylene
90""
2 min or longer (SCT'3pe emulsion off back of slide)
3min
I min
I min
I min
I min
I min
1 min
I min
I min
13. Apply mounting media and glass coverslip. Set aside to dry.
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